Clinical trials: Mental Depression
Depression
A Study of RO4917523 in Patients With Treatment Resistant Depression
This study will evaluate the safety, tolerability and efficacy of RO4917523, in comparison to placebo, in patients with treatment-resistant depression.
- Trial name
- NCT00809562
- Testing
- RO4917523
- Where
- 9 sites in United States
- Volunteers
- 46 people
- Sponsor
- Hoffmann-La Roche
Bipolar Disorder, Bipolar Depression
Seroquel in Bipolar Depression Versus Lithium
This study is being carried out to see if quetiapine fumarate (Seroquel) is effective in treating bipolar depression during an 8-week acute phase compared with placebo and lithium, followed by continuation treatment for 26 up to…
- Conditions
- Bipolar Disorder, Bipolar Depression, Depression
- Trial name
- NCT00206141
- Testing
- Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)
- Where
- 76 sites in Canada, Croatia and 14 more
- Volunteers
- 672 people
- Sponsor
- AstraZeneca
Depression
Internet-Based Treatment of Depression: Comparing Guided With Unguided Self-Help
The study is a randomized controlled trial and to compare the benefits of a 10-week web-based unguided self-help treatment with the same intervention complemented with weekly therapist support via e-mail.
- Trial name
- NCT04428450
- Testing
- Deprexis
- Volunteers
- 76 people
- Sponsor
- Gaia AG
Depressive Disorder
An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder
The purpose of the study is to evaluate the efficacy of SSR149415 in the treatment of Major Depressive Disorder, defined as a change from baseline to visit 7 in the Hamilton Depression Rating Scale.
- Trial name
- LENA (NCT00361491)
- Testing
- SSR149415
- Where
- 7 sites in Argentina, Bulgaria and 5 more
- Volunteers
- 324 people
- Sponsor
- Sanofi
Depressive Disorder, Major
Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder
A six week, fixed dose, double-blind, double-dummy, placebo, and active controlled, multicentre trial to evaluate the safety and efficacy of CP-316,311 in outpatients with major depressive disorder.
- Trial name
- NCT00143091
- Testing
- CP-316,311, Sertraline
- Where
- 10 sites in United States, Russia and 1 more
- Volunteers
- 200 people
- Sponsor
- Pfizer
Major Depressive Disorder
A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive Disorder
A multicenter, 10-week study to evaluate the efficacy and safety of Sustained-Release Desvenlafaxine Hydrochloride versus Sustained-Release venlafaxine Hydrochloride in adult with major depressive disorder.
- Trial name
- NCT01977378
- Testing
- Sustained-Release Desvenlafaxine Hydrochloride, Sustained-Release Venlafaxine Hydrochloride
- Where
- 6 sites in China
- Volunteers
- 300 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Major Depressive Disorder
Study With Vortioxetine on Emotional Functioning in Patients With Depression
The study will evaluate effectiveness of flexible dose vortioxetine 10-20 mg/day on emotional functioning in patients with MDD with an inadequate response to SSRIs/SNRIs.
- Trial name
- COMPLETE (NCT03835715)
- Testing
- Vortioxetine
- Where
- 23 sites in France, Italy and 2 more
- Volunteers
- 150 people
- Sponsor
- H. Lundbeck A/S
Depression, Depressive Disorders
A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)
The primary purpose of this study is to determine whether subjects with psychotic major depression benefit from adjunctive treatment with Org 34517.
- Conditions
- Depression, Depressive Disorders, Psychotic Disorders
- Trial name
- Hermes (NCT00212797)
- Testing
- Org 34517
- Volunteers
- 273 people
- Sponsor
- Merck Sharp & Dohme LLC
Major Depressive Disorder
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
This is a 6-month, open-label, flexible-dose study evaluating desvenlafaxine succinate sustained release (DVS SR) in the treatment of child and adolescent outpatients with major depressive disorder (MDD).
- Trial name
- NCT01371721
- Testing
- DVS SR
- Where
- 35 sites in United States, Mexico
- Volunteers
- 269 people
- Sponsor
- Pfizer
Depression in Remission
A Study of SDI-118 in Participants in Remission From Depression
This is a multi-center, double-blind, randomized, placebo-controlled study to determine the safety, tolerability, and pharmacodynamics of SDI-118 in a once daily (QD) dosing regimen on male and female study participants reporting…
- Trial name
- NCT05212116
- Testing
- SDI-118
- Where
- 3 sites in United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Syndesi Therapeutics
Major Depressive Disorder, Dementia
Vortioxetine in Patients With Depression and Early Dementia
This study evaluates the effectiveness of vortioxetine on depressive symptoms in patients with depression and early dementia
- Trial name
- MEMORY (NCT04294654)
- Testing
- Vortioxetine
- Where
- 24 sites in Estonia, France and 4 more
- Volunteers
- 82 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
To evaluate the long-term efficacy and safety of brexpiprazole as an adjunctive treatment to an antidepressant treatment (ADT) for adult patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01838681
- Testing
- Brexpiprazole, ADT
- Where
- 107 sites in United States, Bulgaria and 14 more
- Volunteers
- 1,986 people
- Sponsor
- H. Lundbeck A/S
Treatment Resistant Depression
Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)
The primary objective of this study is to assess the long-term efficacy of psilocybin with respect to use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the…
- Trial name
- NCT04519957
- Where
- 8 sites in United States, Czechia and 3 more
- Volunteers
- 66 people
- Sponsor
- COMPASS Pathways
Postpartum Depression
Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum Depression
This is an expanded access program intended to provide access to ZULRESSO™ (brexanolone) injection for the treatment of a limited number of eligible women with postpartum depression during the period prior to commercial…
- Trial name
- NCT03924492
- Testing
- ZULRESSO (brexanolone) injection
- Sponsor
- Supernus Pharmaceuticals, Inc.
Depressive Disorder, Treatment-Resistant
Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression
This study evaluated the efficacy and safety of the compound MIJ821 compared to placebo in patients aged from 18 to 65 years diagnosed with treatment-resistant depression. The study was conducted in the US and in Europe (Spain).
- Trial name
- NCT03756129
- Testing
- MIJ821, Ketamine
- Where
- 12 sites in United States, Spain
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Major Depressive Disorder (MDD)
Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive Disorder
This trial includes a short-term study and a long-term study. The short-term study is a multicenter, randomized, double-Blind, double-Dummy, Parallel-Controlled study with a 6-week duration.
- Trial name
- NCT07741331
- Testing
- KH607 tablets, Vortioxetine Hydrobromide Tablets, Part B: KH607
- Volunteers
- 326 people
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Bipolar I Disorder
Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder
The purpose of this study is to determine whether quetiapine when used as adjunct to lithium or divalproex is safe and effective in the maintenance treatment of adult patients with Bipolar I Disorder.
- Trial name
- NCT00107731
- Testing
- quetiapine fumarate, lithium, divalproex
- Where
- 166 sites in United States, Australia and 16 more
- Volunteers
- 710 people
- Sponsor
- AstraZeneca
Depressive Disorder, Major
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
This is a 6-week, randomised, multicenter, double-blind, placebo controlled, fixed dose parallel group study to assess the efficacy and safety of orvepitant (30 and 60 mg/day) versus placebo in subjects with a diagnosis of a…
- Trial name
- orvepitant MDD (NCT00880399)
- Testing
- orvepitant
- Where
- 20 sites in United States, Canada
- Volunteers
- 328 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders
The purpose of this study is to evaluate the efficacy of quetiapine SR in combination with an antidepressant versus an antidepressant alone in patients with MDD with inadequate response to an antidepressant treatment.
- Trial name
- PEARL (NCT00326105)
- Testing
- Quetiapine fumarate
- Where
- 56 sites in United States
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder
The purpose of this study was to further characterize the efficacy, safety, and tolerability of a single fixed dose level of vilazodone compared to placebo in patients with major depressive disorder.
- Trial name
- NCT01473394
- Testing
- Vilazodone
- Where
- 14 sites in United States
- Volunteers
- 518 people
- Sponsor
- Forest Laboratories
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.